XCAN Stock Overview
Xtrackers MSCI Canada ESG Screened UCITS ETF is an exchange-traded fund launched by Deutsche Asset Management S.A.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Xtrackers MSCI Canada ESG Screened UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$70.60 |
52 Week High | US$72.26 |
52 Week Low | US$58.86 |
Beta | 0 |
1 Month Change | -1.79% |
3 Month Change | 2.01% |
1 Year Change | 10.92% |
3 Year Change | 23.10% |
5 Year Change | 49.75% |
Change since IPO | 123.06% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
XCAN | IT Capital Markets | IT Market | |
---|---|---|---|
7D | 0.7% | 1.6% | 1.0% |
1Y | 10.9% | 16.3% | 19.7% |
Return vs Industry: XCAN underperformed the Italian Capital Markets industry which returned 16.3% over the past year.
Return vs Market: XCAN underperformed the Italian Market which returned 19.7% over the past year.
Price Volatility
XCAN volatility | |
---|---|
XCAN Average Weekly Movement | 1.7% |
Capital Markets Industry Average Movement | 3.2% |
Market Average Movement | 4.4% |
10% most volatile stocks in IT Market | 7.5% |
10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: XCAN has not had significant price volatility in the past 3 months.
Volatility Over Time: XCAN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | n/a | etf.dws.com/LUX/ENG/ETF/LU0476289540/-/MSCI-Canada-Index-UCITS-ETF |
Xtrackers MSCI Canada ESG Screened UCITS ETF is an exchange-traded fund launched by Deutsche Asset Management S.A. The fund is co-managed by Deutsche Asset Management Investment GmbH and Deutsche Asset Management (UK) Limited. It invests in the public equity markets of Canada.
Xtrackers MSCI Canada ESG Screened UCITS ETF Fundamentals Summary
XCAN fundamental statistics | |
---|---|
Market cap | €326.59m |
Earnings (TTM) | €0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs XCAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XCAN income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €0 |
Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did XCAN perform over the long term?
See historical performance and comparison